Related Experiment Video
Updated: Feb 14, 2026
06:12
Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model
Published on: May 29, 2015
7.7K
HP-228 (Trega Biosciences Inc)
1Zen Bio Inc, 3200 Chapel Hill-Nelson Blvd, Suite 102, PO Box 12503, Research Triangle Park, NC 27709, USA. zenbio@mindspring.com
Idrugs : the Investigational Drugs Journal
|August 30, 2005
Abstract:
HP-228 is a cytokine regulating agent from Trega Biosciences (formerly Houghten Pharmaceuticals). It is in phase II trials for the management of post-surgical pain and inflammation [195065]. The drug was indicated for the treatment of diabetes, obesity and chemotherapy-induced toxicity, but Trega has decided to discontinue the development of HP-228 for these indications [259339].
